Background: Despite multiple therapeutic approaches for nephrogenic systemic fibrosis (NSF), no single treatment has convincingly shown consistent benefit. The most successful outcomes have been associated with recovery of renal function, although evidence remains limited and past studies have been inconclusive.
INTRODUCTION
Nephrogenic systemic fibrosis (NSF) is a multisystem fibrosing condition seen almost exclusively in patients with renal impairment exposed to gadolinium via contrast-enhanced magnetic resonance imaging (MRI) or magnetic resonance angiography (MRA). In the vast majority of cases, NSF occurs in patients with significant renal impairment. Clinically, 2 They also classified agents as high, medium, or low risk. After the publication of these guidelines, there has been a reduction in the number of new cases of NSF, and no new reports in children have occurred. 3 Confirmed cases of NSF are more common in middle-aged adults but have also been described in children and the elderly, with no significant sex or racial predilection.
There is no standard therapy. Prevention of this disease by avoiding the use of gadolinium-based contrast agents in patients with renal failure is the best course of action. Therapies with some reported benefit include topical corticosteroids, systemic corticosteroids, cyclophosphamide, thalidomide, plasmapheresis, intravenous immunoglobulin, imatinib, rapamycin, intralesional interferon alpha, topical calcipotriene, sodium thiosulfate, extracorporeal photopheresis, and pentoxifylline; however, reported results have been mixed. [2] [3] [4] [5] [6] [7] Despite multiple therapeutic approaches, no single treatment has convincingly shown consistent benefit. In addition, evidence is scarce and drawn only from case reports; case series; and small, uncontrolled trials. The most successful outcomes have been associated with recovery of renal function through either transplantation or resolution of acute kidney injury (AKI) with medical management, although evidence remains limited, and past studies have been inconclusive. 7 One previous study showed improvement with renal transplantation, but 2 others showed more equivocal results. [4] [5] [6] Complete remission has not been reported in the presence of continued renal impairment. We sought to evaluate the long-term follow-up of our patients with NSF. Specifically, we were interested if improvement (subjective or by physician global assessment) was associated with the return of renal function.
METHODS
A retrospective medical chart review was conducted in patients diagnosed with NSF (identified from a dermatopathology data bank) who presented to a single tertiary referral center over a 15-year period, from January 2000 through December 2014. Eight patients were identified, all of whom had a clinical and histopathologic diagnosis of NSF. If necessary, the patients were also contacted by phone to obtain information related to treatment and clinical course of their NSF and renal function. Clinical improvement of NSF was determined by medical chart review via dermatologist global assessment and telephone interview via patient subjective evaluation. Renal function was assessed by evaluation of creatinine, glomerular filtration rate values, and functional status (hemodialysis dependency or designation as end-stage renal disease [ESRD]) via chart review and patient report during telephone interviews. Variables assessed include age, sex, type of renal failure, renal transplant status and outcome, and NSF status (extent of involvement, induration, pain, and limitation of mobility and range of motion).
We performed statistical analysis using Fisher's exact test on the data collected to determine significance. A 2-sided P value \.05 was considered significant. Data was also examined using descriptive statistics and bivariate analyses. The study was approved by the institutional review board at the University of Texas Medical Branch in accordance with the Declaration of Helsinki and the Health Insurance Portability and Accountability Act guidelines.
RESULTS
Eight patients with NSF, who have been previously described, [8] [9] [10] were identified from our dermatopathology data bank. Two had AKI (25%), and 6 had ESRD (75%). The causes of renal failure included
CAPSULE SUMMARY d
Restoration of renal function is the most promising intervention for nephrogenic systemic fibrosis (NSF); however, past studies are inconclusive. Improving renal function should be a main goal of NSF therapy. chronic hypertension, diabetic nephropathy, lupus nephritis, and ESRD after aneurysm repair. For 4 patients, renal function improved, and for 4 patients, renal function did not improve. All 4 patients who had improvement of renal function also had improvement of NSF. Two of these patients had ESRD and a successful kidney transplant, and 2 of these patients had AKI that resolved. In addition, for all 4 patients whose renal function did not improve, their NSF symptoms did not improve. All of these patients were classified as having ESRD. One of these 4 patients had a transplant that failed, and the other 3 did not undergo transplantation. These 4 patients all remained hemodialysis-dependent. No other NSF treatment was effective in our patients. Analysis with Fisher's exact test revealed significant correlation between improvement in renal function and improvement in NSF (P = .0286).
One of our patients (#6) had NSF that developed during an episode of AKI. Thereafter, her renal injury resolved and her NSF symptoms dramatically improved. Several years later, however, her renal function worsened, and she was declared ESRD, after which time the patient remarked that her symptoms of NSF subjectively worsened. She did undergo renal transplantation, but this was unsuccessful, and, per the patient, her NSF did not improve. To our knowledge, no other instances of NSF improvement were not sustained.
Mean patient age was 56.4 years, and a female predominance (62.5%) was observed. All patients were exposed to gadolinium, and the mean time from gadolinium exposure to onset of NSF symptoms was 4.625 (range 1-12) weeks. Mean time from onset of symptoms to evaluation by a dermatologist and diagnosis was 15.4 (range 0.5-45) months. Cumulative gadolinium dose before onset of symptoms was 0.26 mmol/kg over a mean of 2 exposures. Most patients had no functional limitation (75%); however, 2 patients (25%) did have significant functional limitation of rapid onset (\2 months from exposure to onset of symptoms and debilitation). One patient had severe contractures causing him to be wheelchair-bound \2 months after gadolinium exposure; another had significant stiffness causing debilitation within 2 months after exposure. No systemic involvement was reported in the 8 patients. Mean follow-up time was 70.25 (range 4-156) months. Table I summarizes the findings of long term follow-up for our 8 patients with NSF.
DISCUSSION
Current literature suggests that restoration of renal function is the most promising intervention for NSF; however, past evidence has been contradictory. 3 Studies are difficult because of the increasing rarity of the disease after the 2010 FDA-issued black box warning against administration of gadolinium-based contrast agents in at-risk patients. Improvement of NSF after resolution of AKI has been observed in several case reports as well as 2 patients in our study. 5, 7 Others have reported NSF improvement after kidney transplant as well. 5, 7 One possible hypothesis that has been suggested is that improvement in kidney function allows clearance of gadolinium and other fibrotic mediators. [8] [9] [10] Our study is limited by a small sample size (n = 8) and a retrospective design, which increased the potential for selection and recall bias. Even with the small sample size, our results show a significant correlation (P = .0286) with improved renal function and improvement of NSF. These results suggest that improving renal function should be a main goal of NSF therapy. Some previous studies have been more indeterminate. [4] [5] [6] These studies only evaluated the effect of renal transplantation, and their limited length of followup might have been inadequate to ensure that allograft function was ultimately retained. Our results support the theory that renal function is an important factor in the pathogenesis of NSF and its improvement. Further research is needed to determine whether increased renal clearance of gadolinium is the cause of the association between restoration of renal function and improvement of NSF.
CONCLUSION
Improvement of renal function through either transplantation or resolution of AKI with medical management is significantly associated with improvement of the symptoms of NSF. Improvement of NSF symptoms was not attained in the presence of continued renal impairment.
In patients with renal impairment, gadolinium exposure should be avoided. Ultimately identifying the exact mechanism of gadolinium-induced NSF will be beneficial to the development of specific therapies for NSF. Future studies are needed to evaluate if duration or extent of disease before the return of renal function is inversely correlated with greater improvements of NSF symptoms, and if improvement of NSF after return of renal function correlates with decreased levels of gadolinium in the tissue. A return of renal function should be a goal in the treatment of patients with NSF. AKI, Acute kidney failure; ESRD, end-stage renal disease; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; NBUVB, narrow-band ultraviolet B; NSF, nephrogenic systemic fibrosis; PUVA, psoralen ultraviolet A.
